Diclofenac etalhyaluronate - Seikagaku Corporation
Alternative Names: Diclofenac etalhyaluronate sodium - Seikagaku Corporation; Hyaluronic acid/non-steroidal anti-inflammatory drug; Hyaluronic acid/NSAID; JOYCLU; ONO 5704; ONO-5704/SI-613; SI-613; SI-613-ETPLatest Information Update: 30 Nov 2022
At a glance
- Originator Seikagaku Corporation
- Developer Ono Pharmaceutical; Seikagaku Corporation
- Class Amides; Analgesics; Antirheumatics; Drug conjugates; Glycosaminoglycans; Nonsteroidal anti-inflammatories
- Mechanism of Action Cyclooxygenase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Osteoarthritis
- Discontinued Tendinitis
Most Recent Events
- 30 Nov 2022 Discontinued - Phase-II for Tendinitis in Japan (Intra-articular) (Seikagaku Corporation pipeline, November 2022)
- 30 Sep 2022 Seikagaku Corporation plans clinical trial in Osteoarthritis in China and South Korea
- 01 Feb 2022 Seikagaku Corporation terminates a Phase IIb for Tendinitis (Enthesopathy) in Japan, as the trial did not meet the primary efficacy endpoint (Seikagaku Corporation pipeline, November 2022)